Jon Halbert Acquires 68,000 Shares of Caris Life Sciences (NASDAQ:CAI) Stock

Posted by Brenda Bartman on Jul 15th, 2026

Caris Life Sciences, Inc. (NASDAQ:CAI – Get Free Report) Director Jon Halbert bought 68,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were purchased at an average cost of $14.56 per share, with a total value of $990,080.00. Following the acquisition, the director directly owned 704,598 shares of the company’s stock, valued at approximately $10,258,946.88. This trade represents a 10.68% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Caris Life Sciences Price Performance

Shares of NASDAQ CAI opened at $16.95 on Wednesday. Caris Life Sciences, Inc. has a 52 week low of $14.19 and a 52 week high of $42.50. The business’s 50 day moving average price is $17.04 and its 200 day moving average price is $20.06. The company has a quick ratio of 6.52, a current ratio of 7.05 and a debt-to-equity ratio of 0.64. The firm has a market cap of $4.79 billion and a P/E ratio of -2.23.

Caris Life Sciences announced that its Board of Directors has approved a stock repurchase plan on Monday, June 8th that allows the company to buyback $100.00 million in shares. This buyback authorization allows the company to purchase up to 2.1% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on CAI. Wolfe Research cut shares of Caris Life Sciences from an “outperform” rating to a “peer perform” rating in a report on Monday, June 1st. Evercore set a $25.00 price target on shares of Caris Life Sciences in a report on Monday, July 6th. The Goldman Sachs Group started coverage on Caris Life Sciences in a research note on Wednesday, April 1st. They set a “buy” rating and a $27.00 price objective for the company. Weiss Ratings raised Caris Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, May 11th. Finally, Piper Sandler initiated coverage on Caris Life Sciences in a report on Friday, April 10th. They issued a “neutral” rating and a $21.00 price target for the company. Six investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Caris Life Sciences currently has an average rating of “Hold” and an average target price of $26.11.

Check Out Our Latest Analysis on Caris Life Sciences

Hedge Funds Weigh In On Caris Life Sciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CAI. Handelsbanken Fonder AB purchased a new stake in shares of Caris Life Sciences during the second quarter worth about $647,000. Amundi purchased a new position in Caris Life Sciences in the 1st quarter valued at about $375,000. California State Teachers Retirement System boosted its holdings in Caris Life Sciences by 254.5% in the 1st quarter. California State Teachers Retirement System now owns 5,002 shares of the company’s stock worth $89,000 after buying an additional 3,591 shares during the last quarter. Royal Bank of Canada increased its stake in Caris Life Sciences by 101.8% during the 1st quarter. Royal Bank of Canada now owns 18,651 shares of the company’s stock worth $333,000 after buying an additional 9,407 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its stake in Caris Life Sciences by 50.8% during the 1st quarter. The Manufacturers Life Insurance Company now owns 153,512 shares of the company’s stock worth $2,745,000 after buying an additional 51,696 shares in the last quarter.

About Caris Life Sciences

(Get Free Report)

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.